Skip to main content

Table 1 Characteristics of 17 randomized, double-blind, controlled trials included in the meta-analysis

From: Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials

AuthorCountryComorbid,
co-intervention
Doses [mg/day], (n)Duration
(weeks)
HbA1c
at baseline (%)
TG
at baseline (mg/dL)
HDL-C at baseline (mg/dL)LDL-C at baseline (mg/dL)Jadad Scale
Ji
2014 [16]
China,
Korea,
Taiwan
India
Diet and exerciseDAPA: 5 (128), 10 (133),
P: (132)
24DAPA: 8.1, 8.3,
P: 8.4
NRNRNR5
Kadowaki
2014 [17]
JapanDiet and exerciseEMPA: 5 (110), 10 (109),
25 (109), 50 (110), P: (109)
12EMPA: 7.9, 7.9,
7.9, 8.0, P: 7.9
EMPA:148.8, 128.5, 146.2, 148.8, P: 144.4EMPA: 55.3, 58.8
57.7, 57.7, P: 57.3
EMPA: 127.3, 125.0, 125.0, 123.8, P: 124.24
Kashiwagi
2015A [18]
JapanRenal impairment, diet/exercise,
or using an OHA
IPRA: 50 (118),
P: (46)
24IPRA: 7.5, P: 7.5IPRA: 137.6, P: 123.4IPRA: 57.0, P: 56.4IPRA: 114.3,
P: 112.4
5
Lu
2016 [19]
Korea,
Taiwan
Diet, exercise, and metforminIPRA: 50 (87),
P: (83)
24IPRA: 7.7, P: 7.8NRNRNR5
Kashiwagi
2015B [20]
JapanDiet and metforminIPRA: (112), P: (56)24IPRA: 8.3, P: 8.4IPRA: 165.4, P: 129.3IPRA: 53.6, P: 57.4,IPRA: 108.0,
P: 113.6
4
Kashiwagi
2015C [21]
JapanSulfonylureaIPRA: 50 (165), P (75)24IPRA: 8.4, P: 8.3IPRA: 159.6, P: 151.3IPRA: 57.6, P: 58.4IPRA: 124.2,
P: 120.4
5
Kashiwagi
2015D [22]
JapanPioglitazoneIPRA: 50 (97), P: (54)24IPRA: 8.2, P: 8.4IPRA: 142.9, P: 135.2IPRA: 61.1, P: 61.3IPRA: 116.7,
P: 130.4
5
Kashiwagi
2015E [23]
JapanDiet and exerciseIPRA: 50 (62), P: (67)16IPRA: 8.4, P: 8.3IPRA: 159.4, P: 148.1IPRA:56.0, P: 52.1IPRA: 124.4,
P: 127.1
5
Haneda
2016 [24]
JapanRenal impairment, Diet/exercise
or using 1–2 OHAs
LUSEO: 2.5–5.0 (95), P: (50)24LUSEO: 7.7, P: 7.7LUSEO: 147.7, P: 148.1LUSEO:57.7, P:52.9LUSEO: 115.1,
P: 119.3
4
Seino
2014A [25]
JapanDietLUSEO: 2.5 (79), P: (79)24LUSEO: 8.1, P: 8.2LUSEO: 149.5, P: 141.5LUSEO: 58. 0,
P: 60.2
LUSEO: 131.0,
P: 127.8
5
Seino
2014B [26]
JapanDietLUSEO: 1.0 (55), 2.5 (56),
5 (54), 10 (58), P: (57)
12LUSEO: 7.8, 8.1,
7.9, 8.0, P: 7.9
LUSEO: 156.1, 167.6, 136.2, 124.7, P:165.7LUSEO: 56.7, 53.6,
54.2, 58.7, P: 55.0
LUSEO: 126.1,
128.8, 115.4, 121.4, P: 117.9
5
Seino
2014C [27]
JapanDietLUSEO: 0.5 (60), 2.5 (61),
5 (61), P: (54)
12LUSEO: 8.2, 8.1,
8.2, P: 7.9
LUSEO: 173.7,
150.2, 160.4, P:170.0
NRNR5
Inagaki
2016 [28]
JapanDiet, exercise, and insulinCANA: 100 (76), P: (70)16CANA: 8.9, P: 8.9CANA: 124.5, P: 144.0CANA: 61.9,
P: 57.6
CANA: 122.4,
P: 121.9
5
Ji
2015 [29]
China,
Malaysia,
Vietnam
Metformin alone
or metformin plus sulfonylurea
CANA: 100 (223), 300 (227), P (226)18CANA: 8.0, 8.0,
P: 7.9
CANA: 163.7, 180.8,
P: 169.1
CANA: 51.0,
48.8, P: 49.1
CANA: 104.3,
100.8, P: 98.3
4
Inagaki
2014 [30]
JapanDiet and exerciseCANA: 100 (90), 200 (88),
P: (93)
24CANA: 8.0, 8.0,
P: 8.0
CANA: 150.9, 148.9,
P: 158.1
CANA: 54.9,
55.3, P: 55.8
CANA: 127.3,
120.1, P: 124.8
5
Inagaki
2013 [31]
JapanDiet and exerciseCANA: 50 (82), 100 (74),
200 (76), 300 (75), P: (75)
12CANA: 8.1, 8.1,
8.1, 8.2, P: 8.0
NRNRNR5
Kaku
2014 [32]
JapanDiet and exerciseTOFO: 10 (57), 20 (58),
40 (58), P: (56)
24TOFO: 8.5, 8.3, 8.4,
P: 8.4
NRNRNR5
  1. CANA canagliflozin, DAPA dapagliflozin, EMPA empagliflozin, IPRA ipragliflozin, LUSEO luseogliflozin, TOFO tofogliflozin, OHA oral hypoglycemic agent, P placebo, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, NR not reported